Ken Cacciatore
Stock Analyst at TD Cowen
(0.33)
# 4,311
Out of 5,090 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $31.20 | +60.26% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $6.93 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.18 | +41.04% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $16.82 | +108.09% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.52 | +1,006.19% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.58 | +796.06% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $9.55 | +371.20% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $16.54 | +2,681.14% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $31.20
Upside: +60.26%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.93
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.18
Upside: +41.04%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $16.82
Upside: +108.09%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.52
Upside: +1,006.19%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.58
Upside: +796.06%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $9.55
Upside: +371.20%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $16.54
Upside: +2,681.14%